Tag: <span>safety</span>

Home / safety
Post

Ivermectin not authorized to prevent or treat COVID-19; It may cause serious health problems

Health Canada has received concerning reports of the use of veterinary ivermectin to prevent or treat COVID-19. Canadians should never consume health products intended for animals because of the potential serious health dangers posed by them. In this light, Health Canada is advising Canadians not to use either the veterinary or human drug versions of...

Post

Neutrogena Beach Defense and Ultra Sheer aerosol spray sunscreens recalled due to elevated benzene levels

Johnson & Johnson Inc. is recalling all lots of Neutrogena Beach Defense and Ultra Sheer children and adult sunscreens, in aerosol spray format, after testing conducted by the company detected elevated levels of benzene. Frequent and long-term exposure (e.g., through the skin and by inhalation) to elevated levels of benzene may pose serious health risks....

Post

Updated information on AstraZeneca/COVISHIELD COVID-19 vaccines

On June 29, 2021, Health Canada issued a Health Product Risk Communication regarding the AstraZeneca/COVISHIELD COVID-19 vaccine: https://healthycanadians.gc.ca/recall-alert-rappel- avis/hc-sc/2021/75389a-eng.php Health Canada has updated the product monograph for the AstraZeneca and COVISHIELD COVID-19 vaccines to add capillary leak syndrome as a potential side effect following vaccination. Patients with a history of capillary leak syndrome should not...

Post

Second Dose COVID-19 Vaccine Type-Interchangeability, Updated on June3, 2021

NACI recommends that persons who received a first dose of the AstraZeneca/COVISHIELD vaccine may receive either AstraZeneca/COVISHIELD vaccine or an mRNA vaccine (Pfizer-BioNTech or Moderna) for their second dose, unless contraindicated. On June 1, the Public Health Agency of Canada released updated recommendations from the National Advisory Committee on Immunization (NACI) on the interchangeability of authorized...

Post

Age eligibility for AstraZeneca COVID-19 vaccine expanded to 40+

The province of Ontario has announced that starting Tuesday, April 20, the AstraZeneca COVID-19 vaccine will be offered to individuals aged 40 and over at pharmacies across the province. Eligible individuals can book an appointment at participating pharmacies by accessing: https://covid-19.ontario.ca/vaccine-locations   Based on the review of data from Europe and the United Kingdom, Health Canada...

Post

More COVID-19 Vaccine Info

 Dear Patients,  As you all know, the first vaccines are being given to higher risk people and health care workers. But we look forward to when we will have access to the vaccine. We do not yet know the place or the timing and we will communicate this when we do.  Some questions have arisen that...

Post

COVID-19 Vaccines

Dear community members and families, In the last few weeks, we have seen significant movement in our understanding of the COVID-19 vaccines. As of today, here is what we know: The vaccines are safe The vaccines approved for use in Canada work by sending a message to our body’s immune system to stimulate our natural immune response....

Post

3 Approved COVID-19 Vaccines Efficacy

Interim results of two large randomized, placebo-controlled trials (RCTs) demonstrate ~95% relative efficacy in preventing COVID-19 (Pfizer, Moderna). The AstraZeneca/Oxford vaccine has ~70% relative efficacy. Absolute benefits will vary with baseline risk and time but if annual risk of developing COVID-19 is 20%, then vaccine would decrease risk to 1% (6% with AstraZeneca/Oxford). These vaccines...

Post

Important Safety Information on ELMIRON (pentosan polysulfate sodium) and the Risk of Pigmentary Maculopathy – Janssen Inc.

Cases of pigmentary maculopathy have been reported with long-term use of ELMIRON. These changes may be irreversible, and retinal and vision changes may progress even after cessation of therapy. This medicine is usually used for urinary symptoms and pain associated with interstitial cystitis, a condition that presents with painful and frequent urination. HMC

Post

Updates to safety labelling for benzodiazepines and benzodiazepine-like drugs

Benzodiazepines and benzodiazepine-like prescription drugs—commonly used to treat sleep and anxiety disorders, certain seizure disorders, and to help relax muscles or relieve muscle pain—can lead to problematic use and substance use disorder. To help mitigate these risks, Health Canada is asking manufacturers to update their safety warnings to include more prominent and consistent messaging for...

Post

Health Canada is temporarily authorizing the use of technical-grade ethanol in hand sanitizer products

 Health Canada has assessed the risks and benefits of hand sanitizers containing technical-grade ethanol and has concluded that, when used as directed and for a short period, the public health benefit to limit the spread of COVID-19 outweighs the risks. Based on its risk assessment, Health Canada is taking action immediately to ensure the safety...

Post

Certain Metformin diabetes drugs recalled due to the presence of NDMA

Ranbaxy Pharmaceuticals Canada Inc. is recalling six lots of its prescription RAN-Metformin drug from the Canadian market. Company testing identified two lots (#AJY8006A and #AJY8007A) with levels of NDMA above what is considered acceptable if the drug were to be taken over a lifetime. The company is recalling an additional four lots (#AJY8005A, #AJY8005B, #AJY8008A...

Post

Update on 2019-nCoV

Canada has had 4 and Ontario 3 confirmed cases as of Feb 3, 2020. This are 29 cases under investigation in Ontario. There were no cases in Peel Region. Worldwide, 17485 confirmed cases and 362 deaths have been reported to date. Airborne droplet and contact precautions are highly recommended. If you have respiratory symptoms and...

  • 1
  • 2